CN1733704A - Synthesis and biological and pharmacological action of betaine salicylate - Google Patents
Synthesis and biological and pharmacological action of betaine salicylate Download PDFInfo
- Publication number
- CN1733704A CN1733704A CN 200410050998 CN200410050998A CN1733704A CN 1733704 A CN1733704 A CN 1733704A CN 200410050998 CN200410050998 CN 200410050998 CN 200410050998 A CN200410050998 A CN 200410050998A CN 1733704 A CN1733704 A CN 1733704A
- Authority
- CN
- China
- Prior art keywords
- ointment
- whitfield
- trimethyl
- glycine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 title claims description 5
- 238000003786 synthesis reaction Methods 0.000 title abstract description 3
- 229940041488 betaine salicylate Drugs 0.000 title description 3
- 230000000144 pharmacologic effect Effects 0.000 title description 2
- CFXSFDXXYYHZFU-UHFFFAOYSA-N 2-hydroxybenzoic acid;2-(trimethylazaniumyl)acetate Chemical compound C[N+](C)(C)CC(O)=O.OC(=O)C1=CC=CC=C1[O-] CFXSFDXXYYHZFU-UHFFFAOYSA-N 0.000 title 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 208000002177 Cataract Diseases 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 7
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 201000008525 senile cataract Diseases 0.000 claims abstract description 6
- 239000007924 injection Substances 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 claims abstract description 5
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 claims description 47
- 230000000694 effects Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 230000004224 protection Effects 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010039966 Senile dementia Diseases 0.000 claims description 7
- 230000000202 analgesic effect Effects 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 230000036592 analgesia Effects 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 230000001857 anti-mycotic effect Effects 0.000 claims description 6
- 239000002543 antimycotic Substances 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 230000003907 kidney function Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000003908 liver function Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- -1 acyl Whitfield's ointment Chemical compound 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- 230000001437 anti-cataract Effects 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 150000001447 alkali salts Chemical class 0.000 claims 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims 2
- 241000335053 Beta vulgaris Species 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 235000021537 Beetroot Nutrition 0.000 claims 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 240000000203 Salix gracilistyla Species 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000012295 chemical reaction liquid Substances 0.000 claims 1
- 238000005352 clarification Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims 1
- 238000000053 physical method Methods 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 2
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 abstract 1
- 230000000702 anti-platelet effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000011505 plaster Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 29
- 241000700159 Rattus Species 0.000 description 21
- PCTBFRSMNZGQBR-UHFFFAOYSA-N CC(N(C)C)C(O)=O.OC(=O)c1ccccc1O Chemical compound CC(N(C)C)C(O)=O.OC(=O)c1ccccc1O PCTBFRSMNZGQBR-UHFFFAOYSA-N 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 208000033892 Hyperhomocysteinemia Diseases 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 241000282461 Canis lupus Species 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000037308 hair color Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000003225 hyperhomocysteinemia Effects 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 229940087766 mydriacyl Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to chemical synthesis for salicylic betaine salt. The product can match with other drugs to external use or take orally as aqua, soft plaster, capsule or injection, which has wide application in reducing fever, easing pain, anti platelet aggregation, anti senile cataract, protecting normal cell, anti atherosclerosis and other functions.
Description
Technical field the present invention relates to the trimethyl-glycine salicylate analgesic, analgesia, anti-inflammatory, platelet aggregation-against, antimycotic, atherosclerosis, the protection normal cell of chemosynthesis and it, the field that prevents effects such as the muddy and protection hepatic and renal function of crystal fibre.
The background technology cardiac and cerebral vascular diseases becomes the human primary cause of the death day by day.These diseases are the overwhelming majority grow up on atherosclerotic basis, therefore how to develop and safeguard cardiovascular normal function, suppress atherosclerotic protective foods and medicine, and this has become problem anxious to be solved.
1, feed to contain the trimethyl-glycine feed for the rat of high sterol mass formed by blood stasis alcoholic hepatitis for a long time, can make homocysteine (homocysteinemia in the blood, Hey) content descends, and hyperhomocysteinemiainjury (hyperhomocysteinemia, HHcy) be the independent risk factor of cardiovascular and cerebrovascular diseases and senile dementia, thereby trimethyl-glycine can suppress progression of atherosclerosis and treatment senile dementia (Cheng Ji, Neil Kaplowitz. homocysteine mass formed by blood stasis, er stress and alcoholic liver injury, Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury.World J Gastroenterol 2004; 10 (12): 1699-1708).
2, a large amount of studies show that; trimethyl-glycine can be by strengthening the expression of heme oxidase; promote that endogenic CO produces in the liver cell; the CO of lower concentration has the protection cell and suppresses apoptotic effect; promote the activity of the sweet cyclase of acid of bird, c-GMP concentration is increased, activate mitogen activated protein kinase (MAPK); suppress apoptotic pathways and promote the synthetic of the interior sweet methionine(Met) of S-gland of liver, the activity of arrestin kinase c (PKC) is protected cell.Nearest studies show that; in bile acide inductive liver injury animals model, trimethyl-glycine can suppress cytochrome C and be released into cytoplasm from plastosome by stablizing mitochondrial membrane; thereby suppress the activation of Caspase-9, finally suppress apoptosis and protection liver cell.
3, trimethyl-glycine is a kind of chemosmosis agent, chemistry betaine by name, and molecular formula is (CH
3)
3NCH
2COOH.Cl/NO
3, molecular weight is 118+35.5/62, its content in plant, vegetables, herbal medicine is abundant, but also chemosynthesis.It generally is used for makeup as a kind of surfactant, toothpaste or high-grade clean-out system.The people is also arranged as Italy's (the country one belongs to's pharmacopeia) abroad, the U.S. is used for the treatment of the nonspecific hepatitis that alcoholic hepatitis and a variety of causes cause, liver cirrhosis (Barak, et al.United States Patent, 5,428,063), and belong to the patent of the nineties in 20th century, and do not come into one's own as yet at present at home (Chinese patent retrieval and literature search).
4, acetysalicylic various effect is well-known.In application process, many new effects constantly are found, and the discovered in recent years acetylsalicylic acid can be used for cataractous inhibition (Wang Xiangqun, Deng, the acetylsalicylic acid control is from the present situation and the prospect of cataract or glaucoma research, foreign medical science ophthalmology fascicle, 1997,21 (4): 211-216).Itself has physiological functions such as antipyretic-antalgic Whitfield's ointment, but it is bigger to GI irritation, now is only limited to external application.In order to reduce its side effect, improve curative effect, just studying salicyclic acid derivatives or its prodrug preparation (Piao Longqia both at home and abroad, Deng, the preparation of two Whitfield's ointment Methionins and analgesic activity thereof, number reason medicine and pharmacology magazine, 1997,10 (4): 341), but the salicylic development of trimethyl-glycine does not appear in the newspapers as yet.Cataract is human common illness in eye, also is the one of the main reasons of blinding, clinical metabolic, the broad variety such as traumatic, senile, congenital of being divided into.The cataractous main medicine of treatment has gsh at present, contains the medicine of SH base, aldose reductase inhibitor etc., but result of treatment is all not exclusively satisfied.
In view of hyperhomocysteinemiainjury (hyperhomocysteinemia, HHcy) be the independent risk factor of cardiovascular and cerebrovascular diseases and senile dementia, it also is the important pathogenic factors of fatty liver and alcoholic liver, diabetes and fatty liver finally can cause cataract, and trimethyl-glycine can reduce the homocysteine in blood and the liver, therefore the inventor imagines trimethyl-glycine and can be used for treating metabolic and senile cataract, prove through animal experiment, the treatment of trimethyl-glycine Whitfield's ointment is respond well by the cataract that semi-lactosi causes, has therefore proposed the present invention and pharmacotoxicological effect thereof.
Summary of the invention the invention provides analgesic, the analgesia, anti-inflammatory, platelet aggregation-against of the chemical synthesis process of trimethyl-glycine salicylate and derivative and it, antimycotic, atherosclerosis, protection normal cell; prevent effects such as crystal fibre muddiness and protection hepatic and renal function; but also oral administration of external application clinically; can be used for analgesic, analgesia, anti-inflammatory, platelet aggregation-against, antimycotic; anti-cataract, anti-hepatitis, ephritis and cardiovascular and cerebrovascular diseases patient's assisting therapy.
Get 138.12g Whitfield's ointment (homemade), add an amount of dehydrated alcohol, add water-soluble 117g trimethyl-glycine (import packing) slowly under stirring then, react completely, concentrate, separate out crystallization to all dissolvings.The dry 252g trimethyl-glycine salicylate that gets, productive rate is 99%.Its reaction formula is as follows:
The trimethyl-glycine salicylate that this paper adopts Whitfield's ointment and trimethyl-glycine to make compares with Whitfield's ointment, favorable solubility in water, and the mouthfeel flavor is sweet, and does not have salicylic puckery and tart flavour, does not also have the bitter taste of trimethyl-glycine, is applicable to oral and intramuscular injection.
This paper adopt trimethyl-glycine salicylate that Whitfield's ointment and trimethyl-glycine make and with acetylsalicylic acid relatively.Pharmacological evaluation shows.Its analgesic effect is apparently higher than acetylsalicylic acid, and toxic action then obviously reduces.
The trimethyl-glycine salicylate that this paper adopts Whitfield's ointment and trimethyl-glycine to make; the effects such as, analgesia analgesic, anti-inflammatory, platelet aggregation-against, antimycotic, protection normal cell except can be used for; also can be used for atherosclerosis, prevent the assisting therapy of crystal fibre muddiness and senile dementia etc.
The trimethyl-glycine salicylate that this paper adopts Whitfield's ointment and trimethyl-glycine to make can also be used for the treatment of acute hepatitis and hepatic fibrosis.
According to the trimethyl-glycine salicylate such use, it can use with other preparation or compatibility of drugs, also can be used as mixed preparation and uses.Can be single or be mixed and made into capsule, oral liquid, granule with other medicines, tablet or injection can oral or intravenous injections.
The present invention is described further below in conjunction with embodiment for embodiment
Embodiment one, gets 138.12g Whitfield's ointment (homemade), adds an amount of dehydrated alcohol to all dissolvings, stirs down to add water-soluble 117g trimethyl-glycine (import packing), reacts completely, concentrates, and separates out crystallization.The dry 253g trimethyl-glycine salicylate that gets, productive rate is 98%.Its reaction formula is as follows:
Embodiment two, get the 117g trimethyl-glycine, use an amount of dissolved in distilled water, add the 138.12g Whitfield's ointment, are stirred to and react completely, are heated to 50 ℃, and concentrating under reduced pressure is separated out crystallization.The dry 254g trimethyl-glycine salicylate that gets, productive rate is 99.9%.Its reaction formula is as follows:
Embodiment three, the trimethyl-glycine salicylate acute toxicity test
According to pre-test result, trimethyl-glycine Whitfield's ointment maximal dose group is set to 2000mg/kg, and all the other each groups are successively decreased with 0.8 geometric progression, are followed successively by 1600mg/kg, 1280mg/kg, 1024mg/kg, 800mg/kg, 640mg/kg, 500mg/kg, 400mg/kg.Gastric infusion, the administration volume is 0.5ml/20g, and the soup compound concentration is respectively 80mg/ml, 64mg/ml, 50mg/ml, 40mg/ml, 32mg/ml, 25mg/ml, 20mg/ml.
Choosing body weight is 80 of 19-21g mouse, is divided into 8 groups at random, and 10 every group, male and female half and half by set dosage intraperitoneal injection, begin after the administration to observe immediately.Animal activity reduces after 5 minutes, has animal that convulsions is arranged, and does not see the 2-14 days interior no animal deads that animal dead is observed later in 2 days, and animal is observed to put to death after 14 days and dissects each organ no abnormality seen of visual inspection.
Test-results shows, intraperitoneal injection of mice trimethyl-glycine Whitfield's ointment LD
50Adopt current dose not measure
Embodiment four, and the trimethyl-glycine salicylate is to rat alcoholic fatty liver and atherosclerotic protection and therapeutic action
One, laboratory animal
Adopt health, sexual maturity, 42 of the SD rats of first quality standard (available from No.1 Military Medical Univ.'s Experimental Animal Center), male and female half and half, body weight 180-200g divides cage to feed.
Two, experimental technique
1. chronic alcoholic fatty liver modeling:
Each all gives 56 liquor of spending every day during organizing rat experiment, on average is added in the tap water with 4ml/100ml and the high lipid food nursing, and the prescription reference literature is also improved, and adopts 88% basal feed, 10% lard, 2% cholesterol.
2. experimental program and grouping.
52 of healthy SD rats are divided into 3 groups at random, 10 of A groups, and as normal group, normal diet and water; B organizes 12 as the alcoholic fatty liver group; 30 of C groups as experimental group, are male and female half and half.B group is killed mouse respectively at experiment back 2,4 or 8W and is got liver, aorta and blood, does pathological section and Serological testing, observes the formation situation of model, the modeling success back alcohol of stopping using.Control group and experimental group continue to raise with high lipid food, and control group is freely drunk water with common; Experiment component is: be divided into three groups, and high dose group, 10, by 2% trimethyl-glycine Whitfield's ointment administration; Middle dosage group, 10, by 1% trimethyl-glycine Whitfield's ointment administration; Low dose group, goes out by 0.5% trimethyl-glycine Whitfield's ointment administration falling rocks by 10; All add in the drinking-water and freely drink.
3. sample preparations
Control rats is got 1 rat at random behind back 4wk and the 8wk and is put to death with the femoral artery depletion method respectively at handling.Get blood and do every Serological testing, get liver and artery after the execution immediately, the back of weighing is fixed with formalin solution, does the routine paraffin wax stripping and slicing, HE dyeing and picric acid sky wolf red colouring, microscopic examination.As treat success, and then put to death whole rats, do the routine paraffin wax stripping and slicing, HE dyeing and picric acid sky wolf red colouring, microscopic examination.
4. detection content
(1) generalized case: the mental status in the animal rearing process, active situation, hair luster, appetite, stool and urine situation etc.Weigh/week.
(2) liver specimens is seen substantially: weigh and observe size, color and luster, quality, tangent plane situation of liver etc.
Liver index=liver weight/body weight
(3) get left lobe of liver 0.2g, make 10% liver homogenate under 4 ℃, use chloroform: methyl alcohol (2: 1v/v) liquid extracting lipid, promptly the supernatant soluble part is measured by the test kit operation steps with enzyme process, and TG represents intrahepatic fat content, and unit represents with the mg/g liver.
(4) serology detects index: gpt (ALT), triglyceride (TG), cholesterol (CHO).
(5) the liver tissues of rats paraffin section is made HE dyeing and picric acid sky wolf red colouring respectively, and light microscopic detects.
5, statistical procedures: measurement data is with (x ± s) expression uses SPSS10.0 software, and measurement data relatively adopts variance analysis between each group, and ranked data are checked with Ridit, and P＜0.05 is that there were significant differences.
Three, result
1, generalized case: at the 9th weekend, the normal rats hair color is bright and new, and it is good to ingest, quick active; Control rats hair color dimness, poor appetite, slow lazyness is moving; Experiment is respectively organized the rat hair color near normal, and appetite is normal, and reaction is quick.
2, liver sample observation substantially: naked eyes sight normal rats liver color and luster is dark red, and tunicle is smooth, clear-cut margin, and tangent plane is moistening; The control group liver volume obviously increases, and whole liver is milk yellow, and sees focal yellow-white sex change kitchen range, the coating anxiety, and the edge circle is blunt, and tangent plane is greasy.Experimental group liver outward appearance is near normal, and color and luster is ruddy, and tunicle is more smooth, and the edge is sharper keen, and tangent plane is more moistening.
3, pathological observation: om observation normal hepatocytes leaflet structure is clear, cell rope marshalling, and sinus hepaticus is normal, and the liver cell kytoplasm is red to be dyed, and does not see cavity or lipoid degeneration, and nuclear structure is clear; Control group shows that hepatic tissue is destructurized, the leaflet boundary is unclear, the disorder of cell rope, and most of sinus hepaticus disappears, the extensive steatosis of liver cell, be the bulla sample more and change, begun to spread, extend to periphery gradually by central Venule, cell volume increases, the fat karyon that attenuates among the born of the same parents is dripped by fat and presses to a side, become seal to guard against sample and change, most of cell cytoplasm is loose, understain, part of hepatocytes disintegration necrosis.It is better that lipid-lowering effect is respectively organized in experiment, no obvious cavity and loose in the liver cell, part of hepatocytes is slight cloudy swelling, fat drips calm less, the liver lobule clear in structure, and the cell rope is arranged more neat, but fat drips calm more, slightly heavy around the sinus hepaticus mild stenosis, central vein than leaflet periphery denaturation degrees, the karyon clear in structure.
5, the trimethyl-glycine Whitfield's ointment is to the influence (table 1) of experimental rat liver exponential sum intrahepatic fat.The result shows that the trimethyl-glycine Whitfield's ointment can obviously reduce lipid content in the liver, and is dose-dependently.
Table 1 trimethyl-glycine Whitfield's ointment to the influence of experimental rat liver index (LI) and intrahepatic fat (x ± s, n=10).
| Liver index (LI) | TG in the liver (mg/g tissue) | |
| Dosage group low dose group in the normal group control group trimethyl-glycine Whitfield's ointment group high dose group | 2.95±0.48 4.16±0.79 3.06±0.88 ** 3.43±0.92 ** 3.81±1.03 | 21.33±5.09 45.06±14.71 23.24±7.02 ** 28.53±5.26 ** 34.67±9.03 * |
P＜0.01, with normal group relatively;
*P＜0.05,
*P＜0.01, with control group relatively.
6, the trimethyl-glycine Whitfield's ointment is to experimental rat ALT, TG, CHO influences (table 2), table 2 shows: but the trimethyl-glycine Whitfield's ointment can obviously reduce the activity concentration of ALT and CHO in the blood, and be dose-dependently, but serum TG concentration rises in the trimethyl-glycine Whitfield's ointment, may promote that fat shifts relevant in the liver outside liver with the trimethyl-glycine Whitfield's ointment.
Table 2 trimethyl-glycine Whitfield's ointment is to mice serum ALT, TG, CHO (x ± s, influence n=10)
| ALT | TG(mmol/L) | CHO(mmol/ L) | |
| Dosage group low dose group in the normal group control group experimental group high dose group | 38.46±2.05 109.23±6.33 42.57±5.78 ** 52.62±6.72 ** 78.11±5.51 * | 1.46±0.38 3.16±0.57 3.86±0.78 * 3.43±0.42 3.21±0.43 | 2.55±0.48 4.07±0.79 2.67±0.67 ** 3.03±0.82 ** 3.21±1.10 * |
P＜0.01, with normal group relatively;
*P＜0.05,
*P＜0.01, with control group relatively.
7, the trimethyl-glycine Whitfield's ointment is to the influence (table 3) of fat in the hepatic tissue.Control group liver fat area and total area ratio percentage ratio obviously increase, and trimethyl-glycine Whitfield's ointment group is compared obvious decline with control group, have significant difference (P＜001) to see Table 3.
Table 3 trimethyl-glycine Whitfield's ointment is to fatty liver rats'liver fat area percent (x ± s, influence n=10)
| The metering total area (mm 2/ liver) | The fat area percent | |
| Dosage group low dose group in the normal group control group trimethyl-glycine Whitfield's ointment group high dose group | 6120.6±2816.7 8120.6±2816.7 6406.5±1106.5 6511.6±827.7 7016.7±832.3 | 3.1±1.3 32.3±10.7 8.81±8.1 ** 12.08±6.7 ** 19.08±11.6 * |
P＜0.01, with normal group relatively;
*P＜0.05,
*P＜0.01, with control group relatively.
Four, the result shows: the trimethyl-glycine Whitfield's ointment can obviously reduce lipopexia in the liver, mouse chronic hepatic injury and opposing liver fatization that protection is caused by alcohol and high fat diet.
Embodiment five, and the trimethyl-glycine Whitfield's ointment is to the influence of subcutaneous injection D-semi-lactosi rat cataract animal model
One, materials and methods
1, laboratory animal Wistar rat (No.1 Military Medical Univ.'s Experimental Animal Center provides), 40, male and female half and half.
2, medicine and reagent semi-lactosi (AR, Shanghai biochemical reagents two factories) are made into 50% injection liquid, and use conventional sterilization back; Trimethyl-glycine salicylate (AR, self-control); Compound takes off product acid amides collyrium (Beijing Double-Crane Modern Medicine Technologies Limited Liability Company), uses for expanding pupil before the microscopy.
3, the foundation of rat D-galactose cataract model: 3w age (21d age) Wistar rat, mean body weight 25 ± 5g, the slit lamp examination lens is transparent behind mydriasis.The equal routine disinfection of animal in nape portion subcutaneous injection 50% semi-lactosi (30ml/kg/d), is equivalent to semi-lactosi 15g/kg/d); Every day 1 time, 30d continuously.
4, experiment grouping: control group, 10; 1% Whitfield's ointment group, 10; 2% trimethyl-glycine Whitfield's ointment group, 10; 0.5% trimethyl-glycine Whitfield's ointment group, 10.Control animals is freely drunk water, and Whitfield's ointment and trimethyl-glycine Whitfield's ointment join in the drinking-water to be drunk.Each treated animal in 7,14,21,30d respectively with compound mydriacyl mydriasis after, with the dynamic change of slit lamp observation crystalline, and by following standard the cataract that takes place is carried out classification and comparison: the I level: lens does not have muddiness; The II level: lens is slightly muddy, and cavity appears in periphery; The III level: lens moderate muddiness, peripheral cavity is expanded to the center, and vaporific muddiness appears in centronucleus; The IV level: lens height muddiness, cavity expand to the nuclear district, and the vaporific muddiness of centronucleus increases the weight of; V level: lens nucleus muddiness, cataract maturation.
5, statistical treatment: data are all used x between each group
2Check.
Two, result:
The muddy situation of each phase crystal of experimental group and control group is (table 4) relatively
Table 4 is respectively organized the comparison (n=20) of rat crystal pathological change behind the injection different time
| 7d | 14d | 21d | 30d | |||||||||||
| I | II | I | II | III | IV | I | II | III | IV | II | III | IV | V | |
| Control group Whitfield's ointment group trimethyl-glycine Whitfield's ointment high dose group low dose group | 2 9 6 8 | 18 - - - | - 6 12 10 | - 10 8 10 | 20 4 - - | - - - - | - 4 10 6 | - 2 8 8 | 2 12 2 3 | 18 2 - 1 | - 4 12 10 | - 2 6 5 | 2 2 2 3 | 18 10 2 2 |
The result shows that Whitfield's ointment can obviously weaken the forming process (with control group significant difference relatively arranged) of semi-lactosi to rat cataract, and to slow down cataractous formation effect especially obvious and trimethyl-glycine is salicylic.
Three, conclusion: the trimethyl-glycine salicylate can obviously slow down experimental cataractous formation.
Embodiment six, the preparation of trimethyl-glycine salicylate (the bright capsule of eye)
Trimethyl-glycine salicylate: 1500g
Auxiliary material (Zinic stearas/Magnesium Stearate, Microcrystalline Cellulose etc.) 500g balanced mix is even, encapsulated 10000.Also can be pressed into tablet.
Usage: 0.2-0.6g/ time, three times/day.Purposes: be used for the prevention and the treatment of senile cataract.
Embodiment seven, the preparation of trimethyl-glycine salicylate eye ointment or collyrium.
The trimethyl-glycine Whitfield's ointment of 0.1-3%, preferred 0.5%, add relevant auxiliary materials, accents pH is 6.5-7.5, branch 10-50ml flexible pipe or Glass tubing.
Usage: external application is used for the treatment of senile cataract.
Embodiment eight, the preparation of compound betaine salicylate (the bright capsule of compound eye)
Trimethyl-glycine salicylate: 1500g
Vitamin-E 0-500g, preferred 50g;
Vitamin A 0-10g, preferred 3g;
VitaminB10-20mg, preferred 3mg;
Wei ShengsuB2 0-20g, preferred 4g;
Vitamin B6 0-40g, preferred 5g;
Vitamin B12 0-200mg, preferred 30mg;
Vitamins C 0-2000g, preferred 300g;
Folic acid 0-20g, preferred 2g;
Vitamin H, 0-2000mg, preferred 200mg;
Pantothenic acid, 0-200g, preferred 20g;
Nicotinic acid, 0-2000g, preferred 100g;
Various trace elements, auxiliary material (Zinic stearas/Magnesium Stearate, Microcrystalline Cellulose etc.) 100g balanced mix is even, encapsulated 10000.Also can be made into tablet.
Usage: 0.2-0.6g/ time, three times/day.Purposes: be used for the prevention and the treatment of senile cataract.
Embodiment nine, the preparation of compound betaine salicylate (compound heart and brain curing capsule)
Trimethyl-glycine salicylate: 1500g
Arginine 10-5000g, preferred 500g;
Vitamin-E 0-500g, preferred 50g;
Vitamin A 0-10g, preferred 3g;
VITMAIN B1 0-20mg, preferred 3mg;
Wei ShengsuB2 0-20g, preferred 4g;
Vitamin B6 0-40g, preferred 5g;
Vitamin B12 0-200mg, preferred 30mg;
Vitamins C 0-2000g, preferred 300g;
Folic acid 0-20g, preferred 2g;
Vitamin H, 0-2000mg, preferred 200mg;
Pantothenic acid, 0-200g, preferred 20g;
Nicotinic acid, 0-2000g, preferred 100g;
Various trace elements, auxiliary material (Zinic stearas/Magnesium Stearate, Microcrystalline Cellulose etc.) 500g balanced mix is even, encapsulated 10000.Also can be pressed into tablet.
Usage: 0.8-0.9g/ time, three times/day.Purposes: be used for the prevention and the treatment of cardiovascular and cerebrovascular diseases, atherosclerosis, senile dementia.
Claims (9)
1, is applicable to analgesic, analgesia, anti-inflammatory, platelet aggregation-against, antimycotic, anti-senile dementia; anti-ageing year cataract, atherosclerosis, protection normal cell; with the trimethyl-glycine Whitfield's ointment and corresponding isomer and the preparation method that protect effects such as hepatic and renal function; it is characterized in that: garden beet alkali and Whitfield's ointment salify, and represent with following structural:
2, trimethyl-glycine Whitfield's ointment according to claim 1 and corresponding isomer and preparation method, it is characterized in that: described preparation method is as follows: an amount of dissolved in distilled water of 1.17g trimethyl-glycine, slowly add the 1.382g Whitfield's ointment, stirring reaction liquid is to clarification, air-dry, lyophilize or vacuum-drying below 60 ℃.
3, preparation method according to claim 1 and 2 is characterized in that: the mol ratio of described Whitfield's ointment and trimethyl-glycine is arbitrary ratio, preferred 1: 2 or 1: 1.
4, preparation method according to claim 1 and 2 is characterized in that: the drying means of described Whitfield's ointment-beet alkali salt, can take any physical method below 60 ℃.
5, preparation method according to claim 1 and 2 is characterized in that: described trimethyl-glycine comprises formyl radical, ethanoyl, propionyl and butyryl radicals-trimethyl-glycine, or arbitrary biological trimethyl-glycine.
6, preparation method according to claim 1 and 2 is characterized in that: described Whitfield's ointment comprises Whitfield's ointment or salicylic resin such as acetylsalicylic acid, or greasiness acyl Whitfield's ointment, and also available arbitrary non-steroid antiphlogiston (as Ibuprofen BP/EP) substitutes Whitfield's ointment.
7, trimethyl-glycine Whitfield's ointment according to claim 1 and 2 and corresponding isomer is characterized in that: they have common bigcatkin willow acidolysis heat, analgesia, anti-inflammatory, platelet aggregation-against, effect such as antimycotic.And has anti-cataract crystal fibre muddiness, protection hepatic and renal function, protection normal cell, effects such as arteriosclerosis patch formation.
8, trimethyl-glycine Whitfield's ointment according to claim 1 and 2 and corresponding isomer; it is characterized in that: they have the acute, chronic hepatitis hepatocyte protection; the protection of acute and chronic nephritis uriniferous tubules, senile dementia, effects such as cardiovascular and cerebrovascular diseases and senile cataract prevention, treatment.
9, Whitfield's ointment beet alkali salt according to claim 1 and 2 and corresponding isomer is characterized in that: Whitfield's ointment beet alkali salt of the present invention can use with other preparation or compatibility of drugs, also can be used as mixed preparation and uses.Can external application or for oral administration, can be single or be mixed and made into external application aqua, finish or creme, ointment medicine or the water-sol with other medicines, also can make capsule, oral liquid, granule, tablet or injection can oral or intravenous injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410050998 CN1733704A (en) | 2004-08-09 | 2004-08-09 | Synthesis and biological and pharmacological action of betaine salicylate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410050998 CN1733704A (en) | 2004-08-09 | 2004-08-09 | Synthesis and biological and pharmacological action of betaine salicylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1733704A true CN1733704A (en) | 2006-02-15 |
Family
ID=36076358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410050998 Pending CN1733704A (en) | 2004-08-09 | 2004-08-09 | Synthesis and biological and pharmacological action of betaine salicylate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1733704A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110236974A (en) * | 2019-06-14 | 2019-09-17 | 珠海萱嘉君行健康产业发展有限公司 | A kind of toner and preparation method thereof containing glycine betaine salicylic acid ionic liquid |
| CN110294683A (en) * | 2019-05-20 | 2019-10-01 | 深圳市萱嘉生物科技有限公司 | A kind of glycine betaine phenolic acid ion salt and the preparation method and application thereof technical field |
| CN112409198A (en) * | 2019-08-23 | 2021-02-26 | 衢州市展宏生物科技有限公司 | Betaine salicylate and preparation method thereof |
| CN113620827A (en) * | 2021-07-02 | 2021-11-09 | 深圳市萱嘉生物科技有限公司 | Betaine salicylic acid eutectic crystal and preparation method and application thereof |
| CN117017802A (en) * | 2023-08-10 | 2023-11-10 | 上雅(广州)生物基因科技有限公司 | Supermolecule astaxanthin liposome and preparation method and application thereof |
-
2004
- 2004-08-09 CN CN 200410050998 patent/CN1733704A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110294683A (en) * | 2019-05-20 | 2019-10-01 | 深圳市萱嘉生物科技有限公司 | A kind of glycine betaine phenolic acid ion salt and the preparation method and application thereof technical field |
| CN110236974A (en) * | 2019-06-14 | 2019-09-17 | 珠海萱嘉君行健康产业发展有限公司 | A kind of toner and preparation method thereof containing glycine betaine salicylic acid ionic liquid |
| CN112409198A (en) * | 2019-08-23 | 2021-02-26 | 衢州市展宏生物科技有限公司 | Betaine salicylate and preparation method thereof |
| CN113620827A (en) * | 2021-07-02 | 2021-11-09 | 深圳市萱嘉生物科技有限公司 | Betaine salicylic acid eutectic crystal and preparation method and application thereof |
| WO2023274401A1 (en) * | 2021-07-02 | 2023-01-05 | 深圳市萱嘉生物科技有限公司 | Betaine salicylic acid eutectic, preparation method therefor, and application thereof |
| CN117017802A (en) * | 2023-08-10 | 2023-11-10 | 上雅(广州)生物基因科技有限公司 | Supermolecule astaxanthin liposome and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107441078B (en) | A kind of pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1931270A (en) | Sobering up and liver protecting Chinese medicine prepn and its prepn process | |
| CN1850836A (en) | Celosia argentea suponin compound and its pharmaceutical use | |
| CN106474145B (en) | Application of the Polysaccharides from Leaves of Moringa oleifera in preparation prevention and treatment alcoholic liver injury drug and food | |
| CN1557842A (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN1902189A (en) | Plant-origin beta3-adrenoceptor agonist and use of the same | |
| CN1733704A (en) | Synthesis and biological and pharmacological action of betaine salicylate | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1268323C (en) | Rhodiola sacra soft capsule and its preparation | |
| CN101912407A (en) | Weight-reducing and lipid-lowering composition | |
| CN1679648A (en) | Mailuoning injection and its preparation and quality control | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1272290C (en) | Capejasmine cycloolefines ether terpene extract and its preparation method and use | |
| CN1680390A (en) | Halogenated dihydroartemisine, preparation and use thereof | |
| CN1895540A (en) | Medicinal composition for treating cardiovascular disease, its making method and use | |
| CN1506090A (en) | Rheum emodi wall extract and medicine composition with the extract as active component | |
| CN100339090C (en) | Novel pomegranate leaf extract and medicinal use thereof | |
| CN108186693B (en) | Preparation method of paecilomyces hepiali active substance for reducing uric acid or treating hyperuricemia, active substance prepared by method and application thereof | |
| CN106177227A (en) | A kind of compositions containing coenzyme Q10 strengthening body immunity | |
| CN1176697C (en) | Antisenility medicine composition and its prepn | |
| CN111544440A (en) | Application of diosmin and composition in preparation of anti-obesity product | |
| CN1261452C (en) | Sugar latticeing material CHB extracted from serum of turtle or/and tortoise, preparation process and application in pharmacy thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU HEZHU BIOLOGY SCIENCE CO., LTD. Free format text: FORMER OWNER: ZOU QINGYAN Effective date: 20070810 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070810 Address after: 510663 A A502, international business incubator, Guangzhou Science City, Guangzhou economic and Technological Development Zone, Guangdong Applicant after: Guangzhou Hezhu Biotechnology Co., Ltd. Address before: 510620, No. 89, Tianhe straight street, Tianhe District, Guangdong, Guangzhou 701 Applicant before: Zou Qingyan |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20060215 |